Zoetis stock had its Relative Strength (RS) Rating upgraded from 69 to 73 Monday -- a welcome improvement, but still shy of the 80 or higher score you look for.
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD's unique rating tracks share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks tend to have an RS Rating of over 80 as they launch their biggest runs. See if Zoetis stock can continue to rebound and clear that threshold.
Looking For Winning Stocks? Try This Simple Routine
Is Zoetis Stock A Buy?
Zoetis stock is working on a flat base with a 176.76 buy point. See if it can clear the breakout price in heavy trading. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
Earnings grew 15% last quarter, up from -3% in the prior report. Revenue also increased, from 1% to 4%.
Zoetis stock holds the No. 5 rank among its peers in the Medical-Ethical Drugs industry group. Sanofi ADR and Takeda Pharmaceutical ADR are also among the group's highest-rated stocks. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
